279 related articles for article (PubMed ID: 30287678)
1. Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage
Duperret EK; Trautz A; Stoltz R; Patel A; Wise MC; Perales-Puchalt A; Smith T; Broderick KE; Masteller E; Kim JJ; Humeau L; Muthumani K; Weiner DB
Cancer Res; 2018 Nov; 78(22):6363-6370. PubMed ID: 30287678
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.
Kim H; Danishmalik SN; Hwang H; Sin JI; Oh J; Cho Y; Lee H; Jeong M; Kim SH; Hong HJ
Cancer Gene Ther; 2016 Oct; 23(10):341-347. PubMed ID: 27632934
[TBL] [Abstract][Full Text] [Related]
3. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
6. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
[TBL] [Abstract][Full Text] [Related]
7. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.
Dias JD; Hemminki O; Diaconu I; Hirvinen M; Bonetti A; Guse K; Escutenaire S; Kanerva A; Pesonen S; Löskog A; Cerullo V; Hemminki A
Gene Ther; 2012 Oct; 19(10):988-98. PubMed ID: 22071969
[TBL] [Abstract][Full Text] [Related]
8. Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection.
Parzych EM; Gulati S; Zheng B; Bah MA; Elliott STC; Chu JD; Nowak N; Reed GW; Beurskens FJ; Schuurman J; Rice PA; Weiner DB; Ram S
mBio; 2021 Mar; 12(2):. PubMed ID: 33727348
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Du X; Liu M; Su J; Zhang P; Tang F; Ye P; Devenport M; Wang X; Zhang Y; Liu Y; Zheng P
Cell Res; 2018 Apr; 28(4):433-447. PubMed ID: 29463898
[TBL] [Abstract][Full Text] [Related]
10. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
11. Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Ingram JR; Blomberg OS; Rashidian M; Ali L; Garforth S; Fedorov E; Fedorov AA; Bonanno JB; Le Gall C; Crowley S; Espinosa C; Biary T; Keliher EJ; Weissleder R; Almo SC; Dougan SK; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):3912-3917. PubMed ID: 29581255
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint combinations from mouse to man.
Ai M; Curran MA
Cancer Immunol Immunother; 2015 Jul; 64(7):885-92. PubMed ID: 25555570
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression.
Gao C; Gardner D; Theobalds MC; Hitchcock S; Deutsch H; Amuzie C; Cesaroni M; Sargsyan D; Rao TS; Malaviya R
Clin Exp Immunol; 2021 Dec; 206(3):422-438. PubMed ID: 34487545
[TBL] [Abstract][Full Text] [Related]
15. DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure.
Jacobs L; De Smidt E; Geukens N; Declerck P; Hollevoet K
Mol Ther; 2020 Apr; 28(4):1068-1077. PubMed ID: 32101701
[TBL] [Abstract][Full Text] [Related]
16. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
18. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
Okoye IS; Xu L; Walker J; Elahi S
Cancer Immunol Immunother; 2020 Aug; 69(8):1423-1436. PubMed ID: 32246174
[TBL] [Abstract][Full Text] [Related]
19. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP
J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]